- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Acrivon Therapeutics Inc (ACRV)
Acrivon Therapeutics Inc stock price live, this page displays NASDAQ ACRV stock exchange data. View the ACRV premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Acrivon Therapeutics Inc real time stock price chart below.
What Is the Acrivon Therapeutics Inc Stock Price Today?
The Acrivon Therapeutics Inc stock price today is 2.13.
What Is the Stock Symbol for Acrivon Therapeutics Inc?
The stock symbol for Acrivon Therapeutics Inc is "ACRV."
What Stock Exchange Does Acrivon Therapeutics Inc Trade On?
Acrivon Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Acrivon Therapeutics Inc a Good Stock to Buy?
Determining whether Acrivon Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACRV quote. (ISIN: US0048901096)
What Is the Acrivon Therapeutics Inc Stock Price Today?
The Acrivon Therapeutics Inc stock price today is 2.13.
What Is the Stock Symbol for Acrivon Therapeutics Inc?
The stock symbol for Acrivon Therapeutics Inc is "ACRV."
What Stock Exchange Does Acrivon Therapeutics Inc Trade On?
Acrivon Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Acrivon Therapeutics Inc a Good Stock to Buy?
Determining whether Acrivon Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ACRV quote. (ISIN: US0048901096)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.06
2.14
52 wk Range
1.27
3.56
ACRV is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.062.14
52 wk Range
1.273.56
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ACRV Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
11.50
Upside
+439.91%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings upwards for the upcoming period
Form 4 Acrivon Therapeutics Inc For: 22 June- Investing.com
Form 4 Acrivon Therapeutics Inc For: 24 July- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 11.50
(+439.91% Upside)
Acrivon Therapeutics Inc SWOT Analysis
Precision Oncology | Acrivon's AP3 platform leverages AI and machine learning for targeted cancer therapies, positioning the company as a potential disruptor in oncology |
Clinical Progress | Explore ACR-368's promising results in endometrial cancer and ACR-2316's dual-action approach, with key data releases expected through 2026 |
Market Valuation | With a $49M market cap, analysts set price targets ranging from $6 to $17, suggesting significant upside potential if clinical trials succeed |
Strategic Challenges | Learn how Acrivon navigates a competitive landscape, balancing a focused pipeline against the need for diversification in the rapidly evolving oncology market |
Earnings
Latest Release
Aug 12, 2026
EPS / Forecast
-0.43 / -0.64
Revenue / Forecast
-- / --
Compare ACRV to Peers and Sector
Metrics to compare | ACRV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipACRVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.2x | −2.3x | −0.4x | |
PEG Ratio | −0.08 | −0.05 | 0.00 | |
Price/Book | 1.1x | 3.9x | 2.6x | |
Price / LTM Sales | - | 166.9x | 3.0x | |
Upside (Analyst Target) | 393.0% | 120.5% | 48.7% | |
Fair Value Upside | Unlock | 1.2% | 7.0% | Unlock |
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Acrivon Therapeutics (ACRV) Stock Price Today?
The Acrivon Therapeutics stock price today is 2.13 USD.
What Stock Exchange Does Acrivon Therapeutics Trade On?
Acrivon Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Acrivon Therapeutics?
The stock symbol for Acrivon Therapeutics is "ACRV."
What Is the Acrivon Therapeutics Market Cap?
As of today, Acrivon Therapeutics market cap is 88.28M USD.
What Is Acrivon Therapeutics's Earnings Per Share (TTM)?
The Acrivon Therapeutics EPS (TTM) is -1.88.
When Is the Next Acrivon Therapeutics Earnings Date?
Acrivon Therapeutics will release its next earnings report on Nov 12, 2026.
From a Technical Analysis Perspective, Is ACRV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Acrivon Therapeutics Stock Split?
Acrivon Therapeutics has split 0 times.
How Many Employees Does Acrivon Therapeutics Have?
Acrivon Therapeutics has 75 employees.
What is the current trading status of Acrivon Therapeutics (ACRV)?
As of Sep 05, 2026, Acrivon Therapeutics (ACRV) is trading at a price of 2.13 USD, with a previous close of 2.06 USD. The stock has fluctuated within a day range of 2.06 USD to 2.14 USD, while its 52-week range spans from 1.27 USD to 3.56 USD.
What Is Acrivon Therapeutics (ACRV) Price Target According to Analysts?
The average 12-month price target for Acrivon Therapeutics is 11.50 USD, with a high estimate of 19 USD and a low estimate of 7 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +439.91% Upside potential.
What Is the ACRV Premarket Price?
ACRV's last pre-market stock price is 2.07 USD. The pre-market share volume is 4,030.00, and the stock has decreased by 0.01, or 0.49%.
What Is the ACRV After Hours Price?
ACRV's last after hours stock price is 2.18 USD, the stock has decreased by 0.05, or 2.35%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.